• Vadim I. Mazurov
  • Alexey L. Maslyanskiy
  • Kira E. Zotkina
  • Stanislava S. Benevolenskaya
  • Dmitry V. Motorin
  • Andrey Yu Zaritskiy
  • Elizaveta A. Vasilenko
  • Alexey A. Vasilenko
  • Anna M. Titova

One of the methods of treating severe forms of systemic scleroderma is hematopoietic stem-cell autotransplantation (auto-HSCT). The article describes two clinical cases of auto-HSCT followed by rituximab (RTM) therapy in patients with diffuse systemic scleroderma with progressive interstitial lung disease (ILD), high immunological activity, high skin score, and an unfavorable prognosis. The assessment of the course of these diseases was carried out in the course of dynamic observation of patients for 10–11 years. In all cases, auto-HSCT followed by RTM made it possible to achieve remission / low activity, as well as to stabilize the progressive of ILD.

Translated title of the contributionEXPERIENCE OF SUCCESSFUL AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AN UNFAVORABLE PROGNOSIS OF SYSTEMIC SCLERODERMA
Original languageRussian
Pages (from-to)381-387
Number of pages7
JournalNauchno-Prakticheskaya Revmatologiya
Volume60
Issue number3
DOIs
StatePublished - 10 Jul 2022
Externally publishedYes

    Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

    Research areas

  • autologous bone marrow transplantation, interstitial lung disease, systemic scleroderma

ID: 100703938